A Multi-center, Double-masked, Randomized, Placebo-controlled, Parallel-group Study Evaluating the Safety of KetoNaph Ophthalmic Solution in Healthy, Normal Volunteers

Bausch & Lomb Incorporated0 sites534 target enrollmentJuly 2010

ConditionsAllergic Conjunctivitis

InterventionsKetoNaph Vehicle

DrugsKetoNaph Vehicle

Overview

Phase: Phase 3
Intervention: KetoNaph
Conditions: Allergic Conjunctivitis
Sponsor: Bausch & Lomb Incorporated
Enrollment: 534
Primary Endpoint: Percentage of Participants With at Least One Adverse Event.
Status: Completed
Last Updated: 5 years ago

Overview Investigators Eligibility Criteria Arms & Interventions Outcomes Similar Trials

Overview

Brief Summary

This study is being conducted to evaluate the safety of KetoNaph ophthalmic solution in healthy adult subjects and in pediatric subjects with a history or family history of ocular allergy.

Registry

clinicaltrials.gov

Start Date

July 2010

End Date

October 2010

Last Updated

5 years ago

Study Type

Interventional

Study Design

Parallel

Sex

All

Investigators

Sponsor

Bausch & Lomb Incorporated

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•Subjects less than 18 years of age, have either a history or family history of ocular allergy.
•ocular health within normal limits, including a calculated best-corrected visual acuity of 0.3 logMar or better, in each eye. For subjects under 10 years old who are developmentally unable to use the ETDRS chart, visual acuity will be made using the LEA symbols. For these subjects, 20-foot Snellen equivalent units of 20/63 or better in both eyes will be required.

Exclusion Criteria

•Contraindications or sensitivities to the use of any of the investigational product(s) or their components.
•Subjects less than 18 years of age that have had symptoms and/or signs of allergic conjunctivitis/rhinitis and/or treatment with topical or systemic anti-allergy therapy, or have had a history of ragweed hypersensitivity during the 21-day period prior to visit
•Surgical intervention within three months prior to Visit 1 or during the refractive surgery within the past 6 months.
•A known history of retinal detachment, diabetic retinopathy, or active retinal disease;
•An active ocular infection (bacterial, viral or fungal
•Use of any topical ophthalmic agents other than investigational products during study participation or within 5 days of beginning study treatment.
•Current or anticipated use of contact lenses during study participation or within 5 days of beginning study treatment.
•Current, prior (within 14 days of beginning study treatment) or anticipated use of systemic corticosteroids, and/or any other systemic medications which the Investigator feels may confound study data or interfere with the subject's study participation. Prior (within 21 days of beginning study treatment), current or anticipated use of any topical (including nasal) or systemic anti-allergy medications.
•Intraocular pressure (IOP) that is less than 5 mmHg or greater than 22 mmHg or have a normal IOP with a diagnosis of glaucoma.

Arms & Interventions

KetoNaph

KetoNaph Ophthalmic Solution

Intervention: KetoNaph

Vehicle

Vehicle of KetoNaph Ophthalmic Solution

Intervention: Vehicle

Outcomes

Primary Outcomes

Percentage of Participants With at Least One Adverse Event.

Time Frame: 42 days

An adverse event was defined as unfavorable and unintended sign, symptom, or disease temporally associated with the use of a test article, whether or not considered related to test article.